Assessment of eight HPV vaccination programs implemented in lowest income countries

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Ladner, Joë ^a,e   Besson, Marie Hélène ^b   Hampshire, Rachel ^c   Tapert, Lisa ^c   Chirenje, Mike ^d   Saba, Joseph ^b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b Axios International   (France)

^c Axios Healthcare Development   (United States)

^d UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^e HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Cervical cancerp; HPV vaccination; Low and middle income countries; Program evaluation; Vaccine delivery

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; ASIA; BOLIVIA; CAMEROON; CHILD; DEVELOPING COUNTRY; EVALUATION; FEMALE; HAITI; HEALTH CARE QUALITY; HUMAN; LESOTHO; POVERTY; PREVENTIVE HEALTH SERVICE; QUALITATIVE RESEARCH; UTERINE CERVIX TUMOR;

ASIA; BOLIVIA; CAMEROON; CHILD; DEVELOPING COUNTRIES; FEMALE; HAITI; HUMANS; IMMUNIZATION PROGRAMS; LESOTHO; PAPILLOMAVIRUS VACCINES; POVERTY; PROGRAM EVALUATION; QUALITATIVE RESEARCH; UTERINE CERVICAL NEOPLASMS;

EID: 84865230970     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-370     Document Type: Article

References (24)

1. Ferlay J, Shin H, Baray F, Forman D, Mathers C, Parkin DM, Globocan 2008 Cancer incidence and mortality worldwide in 2008, Lyon: IARC 2010 available at: http//globocan.iarc.fr (accessed 25th March 2012)
2. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF, IntJ Cancer 2004 109 418 424 10.1002/ijc.11719 (Pubitemid 38252771)
3. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. J Pathol 1999 189 12 19 10.1002/(SICI)1096-9896(199909)189:1<12::AID- PATH431>3.0.CO;2-F 10451482 (Pubitemid 29406813)
4. Epidemiologic classification of human papillomavirus types associated with cervical cancer. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. N Engl J Med 2003 348 518 527 10.1056/NEJMoa021641 12571259 (Pubitemid 36159887)
5. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The FUTURE II Study Group, N Eng J Med 2007 356 1915 1927
6. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papilloma virus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Lancet 2007 369 2161 2170 10.1016/S0140-6736(07)60946-5 17602732 (Pubitemid 46977438)
7. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Lancet 2009 374 301 314 10.1016/S0140-6736(09)61248-4 19586656
8. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18L1 virus-like particle vaccine through 5years of follow-up. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. Br J Cancer 2006 95 1459 1466 10.1038/sj.bjc.6603469 17117182 (Pubitemid 44863348)
9. Evaluating human papillomavirus vaccination programs. Taira AV, Neukermans CP, Sanders GD, Emerg Infect Dis 2004 11 1915 1923 (Pubitemid 39458555)
10. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Franco EL, Tsu V, Herrero R, Lazcano-Ponce E, Hildesheim A, Munoz N, et al. Vaccine 2008 26 Suppl 11 88 95
11. HPV vaccine acceptability in Ghana, West Africa. Coleman MA, Levison J, Sangi-Haghpeykar H, Vaccine 2011 29 3945 3950 10.1016/j.vaccine.2011.03.093 21481327
12. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Bingham A, Drake JK, La Montagne DS, Arch Pediatr Adolesc Med 2009 163 455 461 10.1001/archpediatrics.2009.50 19414692
13. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Louie KS, de Sanjose S, Mayaud P, Trop Med Int Health 2009 14 1287 1302 10.1111/j.1365-3156.2009.02372.x 19772550
14. Chapter 25: Education, training, and communication for HPV vaccines. Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M, Vaccine 2006 24 Suppl3 210 218
15. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, et al. Vaccine 2006 24 Suppl 3 251 261
16. A Cross-Sectional Study of HPV Vaccine Acceptability in Gaborone. Botswana. DiAngi YT, Panozzo CA, Ramogola-Masire D, Steenhoff AP, Brewer NT, PLoS One 2011 6 25481 10.1371/journal.pone.0025481 22039413
17. Parental acceptance of human papillomavirus (HPV) vaccination in Indonesia: A cross-sectional study. Jaspers L, Budiningsih S, Wolterbeek R, Henderson FC, Peters AA, Vaccine 2011 29 7785 7793 10.1016/j.vaccine.2011.07.107 21821079
18. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Brewer NT, Fazekas KI, Prev Med 2007 45 107 114 10.1016/j.ypmed.2007.05. 013 17628649 (Pubitemid 47348081)
19. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, Kaipilyawar S, et al. Vaccine 2009 27 6203 6209 10.1016/j.vaccine.2009.08.003 19698808
20. Chapter 15: HPV vaccine use in the developing world. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F, Vaccine 2006 24 Suppl 3 132 139
21. Human papillomavirus vaccines WHO position paper, Weekly Epidemiol Rec 2009 84 117 132
22. Qualitative research in health care. Analysing qualitative data. Pope C, Ziebland S, Mays N, BMJ 2000 320 114 116 10.1136/bmj.320.7227.114 10625273
23. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Penny M, Bartolini R, Mosqueira NR, La Montagne DS, Mendoza MA, Ramos I, et al. Vaccine 2011 29 5022 5030 10.1016/j.vaccine.2011.04.078 21609748
24. Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Natunen K, Lehtinen J, Namujju P, Sellors J, Lehtinen M, Infect Dis Obstet Gynecol 2011 2011 675858 21785556